Search results
The Push to Get More People Into Long COVID Studies
Medscape· 2 days agoWhen Ezra Spier was diagnosed with long COVID in late 2022, his main symptom, postexertional malaise, caused fatigue so severe that it forced him to quit...
New Clinical Assessment Tool Improves Dementia Care Actions in Primary Care Patients, NIH Reports
Sierra Sun Times· 10 hours agoResource tripled the odds of receiving dementia-related care within 90 days. June 5, 2024 – A...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 3 days agoFlamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma (HNSCC) PR Newswire LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, June 2, 2024 -Trial-in-Progress poster provides
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors...
The Woonsocket Call· 4 days agoEli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced solid tumors ...
Unpacking Averages: Growth of AL/ML in Medicine as Evidenced by Clinical Trials
The National Law Review· 1 day agoMost people have seen the growth in artificial intelligence/ machine learning (AI/ML)-based medical...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 1 day ago- At Month 18, there was a statistically significant improvement in body proportionality (p-value of 0.001). PALO ALTO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq ...
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024...
Morningstar· 5 days agoTG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing ...
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a...
Morningstar· 6 days agoBiogen Inc. (Nasdaq: BIIB) announced the European Commission (EC) has granted marketing authorization under exceptional circumstances and maintained orphan designation for QALSODY® (tofersen ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 6 days agoBlueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib) PR Newswire CAMBRIDGE, Mass., May ...
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study...
KOIN News 6 Portland· 3 days agoThe abstract was selected for ASCO Daily News coverage.
